Münch Frank, Kohl Matthias, Kwapil Nicola, Dewald Oliver, Cuomo Michela, Purbojo Ariawan
Department of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany.
Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.
Perfusion. 2025 Oct;40(7):1567-1574. doi: 10.1177/02676591241309842. Epub 2024 Dec 21.
BackgroundReliable myocardial protection is essential for a good outcome after arterial switch operation.Patients and MethodsWe evaluated 56 neonates with arterial switch operation in this retrospective study. Three types of cardioplegia were used: antegrade Custodiol® (CCC) = 22, antegrade Custodiol® plus paediatric microplegia (mix) = 14, and antegrade plus retrograde intermittently paediatric microplegia (blood) = 20. We evaluated the extent of myocardial injury using troponin I, Creatine kinase (CK), CK-MB (CK in myocardial cells) and vasoactive inotrope score (VIS), immediately- and the first postoperative day, as well as outcome parameters. A statistical analysis was conducted using multiple linear regression, with adjustments made for the RACHS score and ischemia time, at a significance level of 5%.ResultsPreoperative data were comparable between the three groups. Aortic cross clamp time was significantly different between the three groups (CCC: 115 ± 26 min: mix: 162 ± 35 min: blood: 153 ± 31 min). We found significantly lower troponin I release in the blood group 14 ng/mL [CI95 10; 18] versus CCC group 36 ng/mL [CI95 27; 48] and versus mix group 27 ng/mL [CI95 19; 38]; troponin I 24 h blood group 8 ng/mL [CI95 6; 11] versus CCC group 14 ng/mL [CI95 10; 19]. No significant differences were found in CK, CK-MB, VIS, as well as in outcome parameters 30-day mortality, ventilation time, hospital stay or ECMO implantation.ConclusionsIntermittent paediatric microplegia led to a significantly lower release of troponin I, despite significantly longer ischemia times than after application of Custodiol®. Paediatric microplegia can be safely performed in neonates and also offers the advantage of miniaturization of the Cardiopulmonary bypass setup.
背景
可靠的心肌保护对于动脉调转手术获得良好预后至关重要。
患者与方法
在这项回顾性研究中,我们评估了56例行动脉调转手术的新生儿。使用了三种类型的心脏停搏液:顺行性Custodiol®(CCC)=22例,顺行性Custodiol®加小儿微停搏液(混合)=14例,以及顺行加逆行间歇性小儿微停搏液(血液)=20例。我们在术后即刻及术后第一天使用肌钙蛋白I、肌酸激酶(CK)、CK-MB(心肌细胞中的CK)和血管活性正性肌力评分(VIS)评估心肌损伤程度以及预后参数。采用多元线性回归进行统计分析,并对RACHS评分和缺血时间进行校正,显著性水平为5%。
结果
三组术前数据具有可比性。三组之间主动脉交叉阻断时间存在显著差异(CCC组:115±26分钟;混合组:162±35分钟;血液组:153±31分钟)。我们发现血液组肌钙蛋白I释放显著低于CCC组(血液组14 ng/mL [CI95 10;18],CCC组36 ng/mL [CI95 27;48])和混合组(血液组27 ng/mL [CI95 19;38]);术后24小时血液组肌钙蛋白I为8 ng/mL [CI95 6;11],CCC组为14 ng/mL [CI95 10;19]。在CK、CK-MB、VIS以及30天死亡率、通气时间、住院时间或体外膜肺氧合(ECMO)植入等预后参数方面未发现显著差异。
结论
尽管缺血时间比应用Custodiol®后显著延长,但间歇性小儿微停搏液导致肌钙蛋白I释放显著降低。小儿微停搏液可在新生儿中安全实施,并且还具有使体外循环装置小型化的优势。